RxDoctor Payments DataLook up a doctor →

Mohamed Khan, MD

Interventional Cardiology · Redding, CANPI 1649230988

Payments from drug & device makers

$529,941in general payments, 2019–2025

Across 695 payments — averaging $762.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$224K
  • Janssen Research & Development, LLC$180K
  • Angiodynamics, Inc.$67K
  • AstraZeneca$42K
  • Edwards Lifesciences$3K
  • Abbott$3K
  • plus $12K from 40 others

What the payments were for

  • Travel & lodging$1,2711%
  • Food & beverage$17,67021%
  • Education$2620%
  • Other$66,66778%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529,941 in reported general payments places this provider in the 90th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$6,981,550
Medicare patients
6,686
Services billed
38,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,431$3,488,873
EntrestoSacubitril/Valsartan927$1,430,676
XareltoRivaroxaban691$923,626
JardianceEmpagliflozin429$575,969
Repatha SureclickEvolocumab367$411,962
FarxigaDapagliflozin Propanediol184$227,935
CamzyosMavacamten15$121,969
Praluent PenAlirocumab87$86,377
MultaqDronedarone Hcl37$82,381
Dabigatran EtexilateDabigatran Etexilate Mesylate112$44,862
Rosuvastatin Calcium1,590$36,365
EdarbyclorAzilsartan Med/Chlorthalidone56$34,904
Metoprolol Succinate1,973$32,261
BrilintaTicagrelor32$28,147
Repatha SyringeEvolocumab25$27,916

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$673$3,488,8732,431 claims
NovartisEntresto$830$1,430,676927 claims
Johnson & JohnsonXarelto$736$923,626691 claims
Boehringer IngelheimJardiance$888$575,969429 claims
AstraZenecaFarxiga, Brilinta$42,046$256,082216 claims
E.r. Squibb & Sons, L.L.C.Camzyos$477$121,96915 claims
Esperion Therapeutics, Inc.Nexletol, Nexlizet$422$36,50735 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$12$34,90456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →